JP Morgan's sharp upgrade meets a stubborn short book
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
EchoStar dropped 5.6% over the past week to $86.39, underperforming a peer median decline of 4.4%, even as JP Morgan flipped the stock from Underweight to Overweight with a $144 target on October 16, the kind of two-notch reversal that usually commands attention.
The analyst picture has turned decisively bullish in recent months, yet shorts have barely flinched. JP Morgan's upgrade last Thursday was the most dramatic move, taking the stock from its lowest rating to its highest in a single action. Morgan Stanley assumed coverage at Overweight with a $134 target in September, and UBS upgraded to Buy with a $150 target in early September after previously sitting at Neutral. The consensus is now Buy, with a mean target of $130.20, implying roughly 51% upside from current levels. TD Cowen and Citigroup both trimmed targets after August results but held their Buy ratings. The Street, taken as a whole, has moved from skeptical to constructive since the summer, yet the stock is down 7.6% on the month.
Short interest remains the counterweight. At 17.4% of the free float, the short book is large by any conventional measure and has actually crept up 2.2% over the past week even as individual sessions showed modest covering. FINRA's fortnightly data puts settled short interest at 25.5 million shares with a days-to-cover ratio of 7.21, meaning it would take more than a week of average volume to close the position. Despite that scale, the borrow market is remarkably relaxed: cost to borrow is just 0.56%, up 15% on the week but still in the lowest tier. Availability is at 171%, meaning there are roughly 1.7 shares available to lend for every share already borrowed, well off the 52-week tightest reading of 7.5%. The short score of 71.9 ranks in the 5th percentile for its sector, placing it among the most short-exposed names in the universe, yet the lending market shows no sign of squeeze pressure. Shorts can add cheaply and easily. That combination, high conviction, low friction, is why the position has stayed sticky despite the bullish analyst wave.
Options positioning adds little urgency either way. The put/call ratio of 0.50 is fractionally below its 20-day average of 0.51, with a z-score of -0.50. Earlier in October, the PCR was running closer to 0.53-0.54; the recent drift lower suggests options traders have nudged marginally more toward calls. The move is small enough to read as noise rather than directional conviction. Earnings are due on October 30, nine days away, and the last two results produced next-day gains of 2.4% and 8.9% respectively, with five-day moves of 5.6% and 6.0%. Both prints rewarded holders. The EPS surprise factor score of 95 out of 100 reflects a consistent track record of beating estimates, but the EPS momentum scores, 5 on 30-day and 1 on 90-day, show that forward estimate revisions have been running in the wrong direction lately.
The ownership structure deserves a direct mention. Charles Ergen holds a 13D activist position covering 50.9% of the class, unchanged across his most recent filing in July. His personal holding of 31.7% and the Ergen Family Trust's 18.4% mean the founding family controls more than half the company outright. The activist register is a live fact: Ergen filed a 13D/A as recently as July 31, with 14 total filings since December 2024. Per SEC disclosure rules, these stakes are as last reported and a holder below the 5% threshold has no obligation to file again, but at 50.9% that caveat is academic. What the concentrated ownership does mean practically is that any hostile action is off the table, and the short thesis cannot rest on a change-of-control catalyst. Wellington Management has built a fresh 5.3% passive stake, while FMR (Fidelity) has cut from 10.1% to 1.8% since February, a substantial exit that coincides broadly with the period of share price weakness.
The specific thing to watch is October 30. The short book is too large and too cheap to borrow for the analysts' $130 target to close on its own, something in the results will need to shift the dynamic. The EPS momentum deterioration heading into the print, set against a consistent history of beating, is the central tension the quarter has to resolve.
Stocks in this article
See the live data behind this article on ORTEX.
Open ECHO on ORTEX →How this article was generated
- Generated
- 21 Oct 2026, 19:44
- Data as of
- 21 Oct 2026, 19:43
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.